Chemotherapy News and Research

Latest Chemotherapy News and Research

Scientists develop novel anticancer drug designed to travel through the bloodstream

Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel -- undetected by normal cells -- through the bloodstream until activated by specific cancer proteins.

10 Jul 2012

MammaPrint more cost-effective and clinically-useful test than Oncotype DX

New research from University of the Sciences' Mayes College of Healthcare Business and Policy suggests that MammaPrint - a gene expression profiling (GEP) test used to identify whether women with early-stage breast cancer would benefit from chemotherapy - is the more cost-effective and clinically-useful test than the most frequently used GEP in practice in the United States today.

10 Jul 2012

Protein interactions outside breast cancer cells can permanently stop proliferation

Protein interactions outside breast cancer cells can send signals to the cancer cells to permanently stop proliferating, a new study showed in the School of Medicine at The University of Texas Health Science Center San Antonio.

10 Jul 2012

Novel treatment for cancer based on protein from HIV-1 virus

Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.

9 Jul 2012

Conference highlights utility of zebrafish for human disorder studies

Zebrafish, popular as aquarium fish, now have an important place in research labs as a model organism for studying human diseases.

8 Jul 2012

New Gateway-funded phase II ADAPT study for metastatic colorectal cancer

The Gateway for Cancer Research announces an exciting new Gateway-funded phase II study using ADAPT therapy for treatment of metastatic colorectal cancer based on a 2010 AACR presentation by Dr. Lin and his collaborators.

7 Jul 2012

FDA approves KRAS gene mutation test for colorectal cancer

The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).

7 Jul 2012

Toxins and cell death: Interview with Professor Denise Montell

There are multiple kinds of cell death. Cells can undergo programmed cell death, which is a series of events that undergoes a predictable order at certain times during development.

6 Jul 2012

Anti-cancer activity of HuCAL antibody revealed by new data from OncoMed

MorphoSys AG's (FSE: MOR; Prime Standard Segment, TecDAX) partner OncoMed Pharmaceuticals today announced that Proceedings of the National Academy of Sciences of the United States of America (PNAS) has published online data demonstrating the potent anti-cancer activity of OMP-18R5, a HuCAL antibody targeting the Wnt pathway, in multiple preclinical human tumor models. OMP-18R5 is currently in Phase 1 clinical testing.

5 Jul 2012

Italy's first successful pregnancy and delivery following transplantation of ovarian tissue

Although the first successful preservation of fertility from the freezing, thawing and grafting of ovarian tissue was reported eight years ago, the technique has remained experimental and confined to a few specialist centres. Now, with the announcement of a first pregnancy (and subsequent live birth) in Italy following the transplantation of ovarian tissue, there are indications that fertility preservation is moving into the mainstream of reproductive medicine and into a greater number of centres.

4 Jul 2012

New method promotes selection and growth of dangerous cancer cells

The news a cancer patient most fears is that the disease has spread and become much more difficult to treat. A new method to isolate and grow the most dangerous cancer cells could enable new research into how cancer spreads and, ultimately, how to fight it.

3 Jul 2012

NOTCH1 signaling promotes T-cell acute lymphoblastic leukemia-initiating cell regeneration

Research suggests that patients with leukemia sometimes relapse because standard chemotherapy fails to kill the self-renewing leukemia initiating cells, often referred to as cancer stem cells. In such cancers, the cells lie dormant for a time, only to later begin cloning, resulting in a return and metastasis of the disease.

3 Jul 2012

PGD for breast cancer genes BRCA1/2 is now feasible

Preimplantation genetic diagnosis (PGD) for the breast cancer genes BRCA1/2 is now feasible and established, with good success rates for those treated, according to investigators from the reproduction, oncology and genetics centres of the university hospitals of Maastricht and Brussels.

3 Jul 2012

GRP78 plays an important role in breast cancers that respond to anti-estrogen therapy

Researchers at Georgetown Lombardi Comprehensive Cancer Center have uncovered a single molecule they say is a major determinant of resistance to anti-estrogen therapy used to treat or prevent breast cancer in high-risk women.

3 Jul 2012

Cells close to death from toxin exposure can survive when toxins are removed

The vast majority of cells that appear to be on a one-way track to death after exposure to toxins can bounce back completely after those toxins are removed, Johns Hopkins scientists report in a new study. The finding, published in the June 15 issue of Molecular Biology of the Cell, is not only a testament to the indomitable cellular spirit, but could also offer some practical insight on how to save dying tissues after heart attacks or strokes as well as prevent cancer in cells transiently exposed to toxins.

3 Jul 2012

Study demonstrates effectiveness of combination therapy for breast cancer cells in vitro

A study conducted at Boston University School of Medicine (BUSM) demonstrates an effective combination therapy for breast cancer cells in vitro.

3 Jul 2012

Researchers show how aggressive form of multiple myeloma resists chemotherapy

Researchers at Washington University School of Medicine in St. Louis have shown how an aggressive form of multiple myeloma resists chemotherapy.

3 Jul 2012

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

ImmunoCellular Therapeutics, Ltd., a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it will expand its current Phase IIb trial of ICT-107 from 102 to up to 123 patients with glioblastoma multiforme (GBM) and who are HLA-A1/A2 positive.

2 Jul 2012

Abnormal bone marrow stem cells drive development of myelodysplastic syndromes

Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. The study is published today in the online edition of the journal Blood.

2 Jul 2012

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has successfully completed a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

2 Jul 2012